ACE2-DERIVED PEPTIDES WITH ENHANCED EFFICACY FOR INHIBITION OF SARS-CoV-2 <u>Macarena Duran-Corbera¹</u>, Kamil Makowski¹, Daniel Pulido^{1,2} and Miriam Royo^{1,2} ¹ Institute for Advanced Chemistry of Catalonia-CSIC, Barcelona, Spain. ² Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain. STRATEGY INTRODUCTION The coronavirus disease (COVID-19) has originated the current world-wide pandemic situation. This α-helix stabilization **Cell-infection inhibition of SARS-CoV-2** 2 disease is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Structural It has been reported that the α -helix secondary structure is essential to obtain antiviral activity against SARS-CoV-2. [4] and biochemical characterization has showed that the receptor binding domain (RBD) of the virus Covalent constraints of the peptide candidates will be synthesized surface spike protein interacts with the peptidase to stabilize the desired structure. domain (PD) of angiotensin-converting enzyme 2 ACE2 receptor X (ACE2) [1-3], being this interaction the main induced α-helix is and Peptide entrance mechanism of the virus. constrained via chemical Cytoplasm modifications of the linker. Most of the interactions between RBD and ACE2 Essential amino acids are reside on the helix 1 of ACE2. [4] Design of ACE2 not hindered. X **based peptides** that bind the RBD of SARS-CoV-2 Linker length was calculated could prevent the virus entry to the host cell and Linker Infection by tight-binding DFT theory consequently, reduce the infectivity potential of the virus. **OBJECTIVES Irreversible** inhibitors 4) Multivalent platforms 3 Design and development of ACE2-based peptides inhibitors of SARS-CoV-2. • Different strategies are explored: Long-range macrocycle ACE2 derived peptides with enhanced α -helix structure Covalent bond = Multivalent core Irreversible peptides inhibitors Multivalent inhibitors REFERENCES = Chemically modified peptide = Multivalent platform


[1] P. Karoyan, V. Vieillard, E. Odile, et al. Eur. bioRxiv. 2020, 1-17. [2] J. Shang, G. Ye, K. Shi, et al. Nature. 2020, 581, 221-224. [3] R. Yan, Y. Zhang, Y. Li, et al. Science. 2020, 367, 1444-1448. [4] F. Curreli, S. Victor, X. Tong, et al. MBio. 2020, 11, 1-13.









Chemical modifications of the peptides will be conducted to obtain irreversible versions of the peptides. These should be chemically stable and maintain the binding properties.







Multivalent platforms derivatized with ACE2 based peptide inhibitors may bind synergically to different spike proteins from one virus entity and improve the inhibition efficacy.



